Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 9, 2012, Pages 3475-3480

  Holmes, Kristen M ^a   Annala, Matti ^b   Chua, Corrine Y X ^a   Dunlap, Sarah M ^a,c   Liu, Yuexin ^a   Hugen, Niek ^a,d   Moore, Lynette M ^a   Cogdell, David ^a   Hu, Limei ^a   Nykter, Matti ^b   Hess, Kenneth ^a   Fuller, Gregory N ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c The University of Texas at Austin   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTEGRIN LINKED KINASE; SOMATOMEDIN BINDING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; GLIA CELL; GLIOMA; HUMAN; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGENS, CD29; ASTROCYTOMA; AVIAN PROTEINS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, SIS; GENES, SYNTHETIC; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; I-KAPPA B PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTERMEDIATE FILAMENT PROTEINS; KAPLAN-MEIER ESTIMATE; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; NF-KAPPA B; OLIGODENDROGLIOMA; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, VIRUS; RETROVIRIDAE; SIGNAL TRANSDUCTION;

EID: 84863261004     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120375109     Document Type: Article

References (30)

1. Fuller GN, et al. (1999) Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling. Cancer Res 59:4228-4232. (Pubitemid 29418733)
2. Sallinen SL, et al. (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60:6617-6622.
3. Zhang W, Wang H, Song SW, Fuller GN (2002) Insulin-like growth factor binding protein 2: Gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 12(1):87-94. (Pubitemid 33131365)
4. Dunlap SM, et al. (2007) Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104:11736-11741. (Pubitemid 47175082)
5. Ranke MB, Elmlinger M (1997) Functional role of insulin-like growth factor binding proteins. Horm Res 48(Suppl 4):9-15. (Pubitemid 27464727)
6. Frommer KW, et al. (2006) IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol 37(1):13-23. (Pubitemid 44288602)
7. Wang GK, Hu L, Fuller GN, Zhang W (2006) An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2- induced cell mobility. J Biol Chem 281:14085-14091. (Pubitemid 43848335)
8. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW (2004) Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32:859-868. (Pubitemid 38877689)
9. Hannigan GE, et al. (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379(6560):91-96. (Pubitemid 26008142)
10. Hannigan G, Troussard AA, Dedhar S (2005) Integrin-linked kinase: A cancer therapeutic target unique among its ILK. Nat Rev Cancer 5(1):51-63. (Pubitemid 40052325)
11. Wang H, et al. (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84:941-951. (Pubitemid 39025029)
12. Smith D, Shimamura T, Barbera S, Bejcek BE (2008) NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem 307(1-2):141-147.
13. Xie TX, et al. (2008) Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. Int J Oncol 33 (1):5-15.
14. Bhoopathi P, et al. (2008) Blockade of tumor growth due to matrix metalloproteinase- 9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 283:1545-1552.
15. Tan C, Mui A, Dedhar S (2002) Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J Biol Chem 277:3109-3116. (Pubitemid 34953171)
16. Wani AA, Jafarnejad SM, Zhou J, Li G (2011) Integrin-linked kinase regulates melanoma angiogenesis by activating NF-κB/interleukin-6 signaling pathway. Oncogene 30:2778-2788.
17. Luque A, et al. (1996) Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355- 425) of the common beta 1 chain. J Biol Chem 271:11067-11075. (Pubitemid 26155933)
18. Mould AP, Garratt AN, Askari JA, Akiyama SK, Humphries MJ (1995) Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the beta 1 subunit. FEBS Lett 363(1-2):118-122.
19. Holland EC, Varmus HE (1998) Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 95: 1218-1223. (Pubitemid 28124939)
20. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12:3675-3685. (Pubitemid 29019648)
21. Dai C, et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925. (Pubitemid 32738621)
22. Holland EC (2000) A mouse model for glioma: Biology, pathology, and therapeutic opportunities. Toxicol Pathol 28(1):171-177.
23. Moore LM, Holmes KM, Fuller GN, Zhang W (2011) Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model. Chin J Cancer 30(3):163-172.
24. Moore LM, et al. (2009) IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA 106:16675-16679.
25. Zhang W, Moore L, Ji P (2011) Mouse models for cancer research. Chin J Cancer 30(3): 149-152.
26. Cox D, Brennan M, Moran N (2010) Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov 9:804-820.
27. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P (2010) Integrin signalling adaptors: Not only figurants in the cancer story. Nat Rev Cancer 10:858-870.
28. Kalra J, et al. (2009) QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res 11:R25.
29. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33-40.
30. National Cancer Institute (2005) REMBRANDT. http://rembrandt.nci.nih.gov. Accessed October 11, 2010.